Green, Jennifer B.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,577

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., et al. (2025) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 319

Heart Failure With Preserved Ejection Fraction and Diabetes

McHugh, K., DeVore, A. D., Wu, J., Matsouaka, R. A., Fonarow, G. C., Heidenreich, P. A., Yancy, C. W., Green, J. B., Altman, N., & Hernandez, A. F. (2019) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 313

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 237

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 217

Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 131

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 106

Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial

Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., et al. (2017) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 80

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 78

Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype

Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 76

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Prevalence of microvascular and macrovascular disease in the glycemia reduction approaches in diabetes - a comparative effectiveness (GRADE) study cohort

Mather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 34